Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


EAHAD 2016: Highlight 2 – Hemophilia A

This highlight is dedicated to hemophilia A. The latest updates of the SIPPET, FranceCoag en RODIN studies are presented and we cover original research. You will learn about PDI, a molecule that might (partly) explain variations in bleeding phenotypes. Also, the value of the TGA test is discussed. The highlight ends with a case discussion, which stresses the importance of a multidisciplinary approach and serves to explain the treatment of inhibitors with ITI.

Speakers:

  • Elena Santagostino, MD PhD, Maggiore Hospital Policlinico, Milan: TGA for testing of hemostatic effectiveness of fVIII concentrates in patients with Hemophilia A and inhibitors: in vitro results from the predicTGA study
  • Prof. Cédric Hermans, MD, St-Luc University Hospital, Brussels: Updates on the SIPPET, FranceCoag and RODIN studies: the relationship between specific FVIII concentrate and inhibitor formation
  • Katharina Holstein, MD, University Medical Centre, Hamburg: Expression and release of platelet protein disulfide isomerase (PDI) is increased in patients with hemophilia A
  • Prof. Karin Fijnvandraat, MD, Academisch Medisch Centrum, Amsterdam: Case report - Multidisciplinary approach, treatment of inhibitors with ITI
  • This program is editorially independent and is financially made possible by

Related items

Congress news

EAHAD 2016: Highlight 3 – Musculoskeletal complications

In highlight three, mobility takes the center stage. With hemophilia patient reaching advanced ages, is has become apparent that they have a higher chance of developing osteoporosis. The reasons and treatments of this complications will be explained to you. Other subjects include a new approach to treating inflammation during a joint bleed and joint outcomes in mild hemophilia patients. Speakers: Prof. Alok Srivastava, MD, Christian Medical College, Vellore: Low dose prophylaxis and treatment of joint inflammation caused by joint bleeds Mehdi Osooli, M.Sc., Lund University: Joint outcomes in mild hemophilia: a register based study Björn Rosengren, MD PhD, Skåne University Hospital, Malmö: Managing osteoporosis in hemophilia patients

Congress news

EAHAD 2016: Highlight 1 – Von Willebrand Disease

Two original studies will be covered in the first highlight. In addition, the elements and usefulness of a VWD classification system are discussed. The presenting authors explain why it is important to restage VWD patients using current guidelines, and a controversial topic is breeched: can some VWD2B patients be treated with desmopressin prophylaxis before minor surgery, instead of FVIII concentrate, based on their genotype? Speakers: Carolyn Millar, MD, Hammersmith Hospital, London: The necessity of VWD subclassification Vuokko Jokela, MD, Helsinki University Central Hospital: Impact of platelet function on clinical phenotypes in Von Willebrand Disease: re-evaluation of 83 patient with historical diagnosis Lucia Rugeri, MD, Hôpital Cardiologique, Lyon: Genotyping might help therapeutic decision making in patients with Von Willebrand Disease type 2B (VWD2B)

Congress news

EAHAD 2016: Highlight 3 – Musculoskeletal complications

In highlight three, mobility takes the center stage. With hemophilia patient reaching advanced ages, is has become apparent that they have a higher chance of developing osteoporosis. The reasons and treatments of this complications will be explained to you. Other subjects include a new approach to treating inflammation during a joint bleed and joint outcomes in mild hemophilia patients. Speakers: Prof. Alok Srivastava, MD, Christian Medical College, Vellore: Low dose prophylaxis and treatment of joint inflammation caused by joint bleeds Mehdi Osooli, M.Sc., Lund University: Joint outcomes in mild hemophilia: a register based study Björn Rosengren, MD PhD, Skåne University Hospital, Malmö: Managing osteoporosis in hemophilia patients

Congress news

EAHAD 2016: Highlight 1 – Von Willebrand Disease

Two original studies will be covered in the first highlight. In addition, the elements and usefulness of a VWD classification system are discussed. The presenting authors explain why it is important to restage VWD patients using current guidelines, and a controversial topic is breeched: can some VWD2B patients be treated with desmopressin prophylaxis before minor surgery, instead of FVIII concentrate, based on their genotype? Speakers: Carolyn Millar, MD, Hammersmith Hospital, London: The necessity of VWD subclassification Vuokko Jokela, MD, Helsinki University Central Hospital: Impact of platelet function on clinical phenotypes in Von Willebrand Disease: re-evaluation of 83 patient with historical diagnosis Lucia Rugeri, MD, Hôpital Cardiologique, Lyon: Genotyping might help therapeutic decision making in patients with Von Willebrand Disease type 2B (VWD2B)